CMS confirms national coverage for Cologuard

CMS finalized its National Coverage Determination for the Cologuard non-invasive DNA screening test for colorectal cancer from Exact Sciences Corp. (NASDAQ:EXAS), the first product that has undergone a pilot parallel assessment by the Medicare agency and FDA.

The final NCD confirms the initial CMS draft, establishing national coverage for the test once every three years for asymptomatic beneficiaries aged 50-85 who are at average risk of developing colorectal cancer. ...